Effect of Y‐Element on Microstructure and Mechanical Properties of As‐Cast Mg–3Zn–1Mn Alloy Containing I and W Phase

Abstract

Magnesium (Mg) alloy has a wide range of applications in the biomedical field at present. The Mg–Zn–Mn ternary alloy has excellent corrosion resistance, but the addition of Mn element reduces the ductility of the alloy. In this study, a little rare earth element Y is added to the Mg–Zn–Mn ternary alloy to improve the mechanical properties of the alloy, especially the ductility. Experimental results show that the second phase composition and mechanical properties of the alloys are improved by introducing the new second phase (quasicrystal I phase Mg3Zn6Y and W phase Mg3Zn3Y2). When the content of rare earth element Y is 1 wt%, the mechanical properties of the as‐cast alloy are optimized that the tensile strength is increased by 60 MPa compared with the Mg–Zn–Mn alloy, reaching 198 MPa. The elongation increased from 9% to 21%; therefore, the ductility of the material is greatly improved.

In Response to Precision Medicine: Current Subcellular Targeting Strategies for Cancer Therapy

“…Nanoscale metal organic frameworks (nMOFs) are a type of inorganic NPs consisting of metal inorganic nodes (clusters, chains, or layers of transition metals) and organic ligands (such as carboxylates, phosphonates, or azolates). [ 153 ] Porous nMOF has shown the potential to work as carriers for delivery of therapeutic agents for treatment, [ 154 ] owing to their tunable chemical composition and pore size, high pore volume, short‐term stability, and long‐term biodegradability, thereby setting a solid foundation for loading therapeutics and attaining controlled release in organelles. [ 155 ] For instance, Liu and co‐workers reported TPATrzPy‐3 + @PMOF NPs ( Figure a), [ 156 ] which could be described as a PS generator composed of Cu(II)‐based MOF‐199 and two inert PS precursors, [ 157 ] TPAalkyne‐2 + and MePy‐N 3 .…”

Living Leukocyte‐Based Drug Delivery Systems

“…At the same time, multiple stimuli‐response properties can help drugs eliminate interference to achieve the desired effect and function appropriately under a more complex biological environment in vivo. [ 5,50–53 ] All these studies provide a good direction for future clinical trials and applications.…”

“…[ 1,2 ] For instance, antibiotics and anti‐inflammatory agents are widely applied for bacteria‐induced infectious disease treatment in the clinics, but the off‐targeting effect of these drugs largely affects and limits the function of patients’ immune systems, particularly resulting in antimicrobial resistance and autoimmune diseases. [ 3–5 ] To overcome these obstacles, drug delivery systems (DDSs) are attracting more and more attention among scientists and engineers because they can serve as “Trojan horses” to escort the drug to the target tissue with higher efficacy and lower side effects. [ 6–10 ] DDSs can regulate the distribution of drugs in organisms spatiotemporally to achieve targeted delivery, controlled release, and reduced toxicity/side effects.…”

Metal–Organic Frameworks‐Based Nanoplatforms for the Theranostic Applications of Neurological Diseases

“…For example, liposomes, dendrimers, and micelles typically are subjected to low loading capacities associated with difficulty in controlling drug release, and some inorganic nanomaterials have unacceptable toxicity and undesirable degradability. [ 6 ] An ideal nanoplatform for the administration of neurological diseases should possess the following basic requirements: [ 5 ] 1) NPs should be nontoxic with excellent biocompatibility; 2) NPs should be stable in the blood system accompanied by long time in circulation; 3) NPs could efficiently deliver functional agents; 4) NPs should possess the ability to bypass BBB and achieve targeted and/or controllable drug release; 5) The NPs production process is scalable and cost‐effective.…”